LITAL DECOTIIS: Open Payments
NPI 1538879754 · NEW CITY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 35 payments from 8 companies in 2025. Trend: 2023 $1,082 · 2024 $958 · 2025 $510
Food & beverage: $510
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $278 |
| Janssen Biotech, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Gilead Sciences, Inc. | 2 | $41 |
| Celltrion USA Inc. | 1 | $23 |
| QOL Medical, LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Organon LLC | 1 | $14 |
Products named: RINVOQ, TREMFYA, ENTYVIO, SKYRIZI, VIBERZI, VEGZELMA, CREON, LINZESS.
Industry payments across NY — which companies pay providers there.
